Sequential Treatment of Psoriasis With Integrated Traditional Chinese and Western Medicine
- Conditions
- Plaque Psoriasis
- Interventions
- Device: NB-UVB therapyDrug: Jueyin granulesDrug: Jueyin placebo granulesDevice: moving cupping therapyDevice: NB-UVB placebo phototherapyDevice: moving cupping placebo therapy
- Registration Number
- NCT03941431
- Lead Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
- Brief Summary
The purpose of this study was to explore intervention time of Chinese medicine and specification of a sequential treatment plan for severe psoriasis with Chinese and Western medicine.
- Detailed Description
Psoriasis is a chronic, relapsing, inflammatory disease that seriously affects the quality of life of patients. Both Chinese medicine and Western medicine have many methods for treating psoriasis, each with its own advantages and disadvantages, but the pursuit of green and effective treatment programs is still the focus of the work of specialists and researchers. How to combine the existing safe and effective Chinese and Western medicine methods organically, and to achieve the purpose of improving efficacy under the premise of ensuring safety, is the motivation for carrying out this research.
The treatments involved in this study include cupping, phototherapy, and Chinese medicine. All three methods have sufficient literature to confirm their effectiveness in treating plaque psoriasis. The research team hopes to obtain a best combination of three treatments for plaque psoriasis by using a multicenter, randomized, single-blind, controlled trial.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 378
- Plaque psoriasis, the course of disease is not limited.
- Skin lesions involving ≤ 15% BSA (the lesions are mainly located in the trunk and / or limbs, palm / sole, face / scalp, vulva area is not included).
- 18 to 65 years old, male or female patient.
- Informed consent must be obtained.
- other active skin diseases which may affect the condition assessment are present.
- Patients who received systematic treatment of research drugs, biological agents and immunosuppressive agents within 2 months.
- Patients who received treatment with topical glucocorticoids, phototherapy, etc. within 2 weeks.
- Those with severe, uncontrollable local or systemic acute or chronic infections.
- patients with severe systemic diseases; or clinical test indicators in one of the following cases: alanine transferase or glutamate transferase increased by >1.5 times the upper limit of normal; serum creatinine increased by >1.5 times the upper limit of normal Any of the main blood routine indicators (white blood cell count, red blood cell count, hemoglobin amount, platelet count) below the lower limit of normal; or other laboratory abnormalities judged by the investigator are not suitable for participation in this trial.
- Patients with a history of malignant tumors and patients with primary or secondary immunodeficiency and hypersensitivity.
- Patients underwent major surgery within 8 weeks or will require such surgery during the study period.
- Patients who are pregnant or in lactation.
- Those have a history of alcohol abuse, drug abuse or drug abuse.
- Patients with a history of serious mental illness or family history.
- Patients with a family history of cancer.
- Other reasons that the investigator considered inappropriate to participate in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Chinese medicine external treatment group Jueyin placebo granules Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks. Western medicine treatment group NB-UVB therapy Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks. Chinese medicine treatment group Jueyin granules Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks. Chinese medicine treatment group moving cupping therapy Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks. Chinese medicine treatment group NB-UVB placebo phototherapy Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks. Western medicine treatment group moving cupping placebo therapy Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks. Integrated Chinese and Western Medicine Treatment Group NB-UVB therapy Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks. Chinese medicine internal treatment group Jueyin granules Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks. Chinese medicine internal treatment group moving cupping placebo therapy Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks. Chinese medicine external treatment group moving cupping therapy Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks. Western medicine treatment group Jueyin placebo granules Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks. Integrated Chinese and Western Medicine Treatment Group Jueyin granules Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks. Integrated Chinese and Western Medicine Treatment Group moving cupping therapy Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks.
- Primary Outcome Measures
Name Time Method Psoriasis area and severity index Up to 56 days after treatment. Psoriasis Area and Severity Index involves grading psoriatic plaques based on erythema (E), infiltration (I), desquamation (D). Severity is graded from 0-4 for each criteria (0 - none, 1 - slight, 2 - moderate, 3 - severe, and 4 - very severe). The body is divided into 4 regions, head, upper extremities, trunk, and lower extremities, and for each region, the surface area involvement is graded on a 0-6 scale (0 - 0% involvement, 1 - \<10%, 2 - 10-\<30%, 3 - 30-\<50%, 4 - 50-\<70%, 5 - 70-\<90%, 6 - 90-100%).The highest potential PASI score is 72, with higher PASI scores indicating worse psoriasis.
- Secondary Outcome Measures
Name Time Method Dermatology Life quality index(DLQI) Up to 56 days after treatment. The Dermatology Life Quality Index (DLQI) is a participant-reported questionnaire used to measure the health-related quality of life (QOL) of adults suffering from a skin disease. Scores range from 0-30, a higher score indicating a greater impact on a participant's quality of life.
Physician Global Assessment (PGA) Up to 56 days after treatment. Physician Global Assessment (PGA) is scored on a 5-point scale, reflecting a global consideration of the erythema (E), infiltration (I), desquamation (D) across all psoriatic lesions. It is calculated as follows: PGA score = (E + I + D) / 3, then the score needs to be rounded to the nearest whole number \[PGA scale: Clear (0) - Very Severe (5)\].
Visual Analogue Score (VAS) Up to 56 days after treatment. Visual Analog Scale (VAS) is used to measure lesion pruritus from 0 to 100 mm at eash visit (with 0 being no pruritis and 100 being maximum pruritis).
TCM symptom score Up to 56 days after treatment. The TCM symptom score is used to assess changes in blood syndrome related symptoms during treatment.
Body surface area (BSA) Up to 56 days after treatment. The percentage of BSA involved in psoriasis is estimated by fingerprinting, where the entire palm of the patient represents approximately 1% of the total BSA. The number of handprints on psoriasis skin in a body part is used to determine the extent to which the body part is affected by psoriasis (%)
Patient-reported quality of life (PRQoL) Up to 56 days after treatment. PRQoL is used to assess the impact of psoriasis on individual social life. Scores range from 0-25, a higher score indicating a greater impact on a participant's social life.
Trial Locations
- Locations (6)
Wuhan No.1 Hospital
🇨🇳Wuhan, Hubei, China
The Second People's Hospital Affiliated to Fujian University of TCM
🇨🇳Fuzhou, Fujian, China
Jiangsu Province Hospital of Traditional Chinese Medicine
🇨🇳Nanjing, Jiangsu, China
Chinese Medicine Hospital Affiliated to Southwest Medical University
🇨🇳Luzhou, Sichuan, China
Shanghai Dermatology Hospital
🇨🇳Shanghai, China
Shanghai Yueyang Integrated Medicine Hospital
🇨🇳Shanghai, China